erlotinib has been researched along with 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine in 1 studies
Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine) | Trials (3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine) | Recent Studies (post-2010) (3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine) |
---|---|---|---|---|---|
221 | 0 | 180 | 5 | 0 | 5 |
Protein | Taxonomy | erlotinib (IC50) | 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine (IC50) |
---|---|---|---|
Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 0.092 | |
Hepatocyte growth factor receptor | Homo sapiens (human) | 0.0165 | |
ALK tyrosine kinase receptor | Homo sapiens (human) | 0.3219 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
1 other study(ies) available for erlotinib and 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine
Article | Year |
---|---|
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |